116 related articles for article (PubMed ID: 15269044)
21. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
22. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
23. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
25. The value of positron emission tomography in the follow-up for breast cancer.
Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
[TBL] [Abstract][Full Text] [Related]
26. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
28. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract][Full Text] [Related]
29. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
30. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
Scanga DR; Martin WH; Delbeke D
Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
[TBL] [Abstract][Full Text] [Related]
31. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.
Vranjesevic D; Filmont JE; Meta J; Silverman DH; Phelps ME; Rao J; Valk PE; Czernin J
J Nucl Med; 2002 Mar; 43(3):325-9. PubMed ID: 11884491
[TBL] [Abstract][Full Text] [Related]
32. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients.
Santiago JF; Gonen M; Yeung H; Macapinlac H; Larson S
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):61-7. PubMed ID: 16557205
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
35. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
36. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
37. PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer.
Lei L; Wang X; Chen Z
Adv Clin Exp Med; 2016; 25(2):377-82. PubMed ID: 27627573
[TBL] [Abstract][Full Text] [Related]
38. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management.
Grahek D; Montravers F; Kerrou K; Aide N; Lotz JP; Talbot JN
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):179-88. PubMed ID: 15129699
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases].
Alvarez Pérez RM; Borrego Dorado I; Ruiz Franco-Baux JV; Vázquez Albertino RJ
Rev Esp Med Nucl; 2007; 26(1):30-9. PubMed ID: 17286946
[TBL] [Abstract][Full Text] [Related]
40. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
